NYSE:EVHEvolent Health Stock Price, Forecast & News

Evolent Health's stock was trading at $6.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EVH stock has decreased by 10.5% and is now trading at $6.19. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evolent Health.

Evolent Health is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Evolent Health.

Evolent Health Inc (NYSE:EVH) announced its quarterly earnings data on Thursday, May, 7th. The technology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.01. The technology company had revenue of $247.29 million for the quarter, compared to the consensus estimate of $239.35 million. Evolent Health had a negative net margin of 37.17% and a negative return on equity of 6.09%. View Evolent Health's earnings history.

Evolent Health updated its second quarter 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $236-247 million, compared to the consensus revenue estimate of $240.29 million.

10 brokerages have issued twelve-month price targets for Evolent Health's stock. Their forecasts range from $8.00 to $18.00. On average, they expect Evolent Health's share price to reach $13.42 in the next year. This suggests a possible upside of 116.7% from the stock's current price. View analysts' price targets for Evolent Health.

Headlines about EVH stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evolent Health earned a news impact score of -1.5 on InfoTrie's scale. They also assigned news coverage about the technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutEvolent Health.

Some companies that are related to Evolent Health include R1 RCM (RCM), Franklin Covey (FC), Jupai (JP), PHI Group (PHIL) and Rainmaker Systems (VCTL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Chipotle Mexican Grill (CMG), Energy Transfer LP Unit (ET), Netflix (NFLX), Micron Technology (MU), Advanced Micro Devices (AMD) and Aegean Marine Petroleum Network (ANW).

(EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (7.66%), BlackRock Inc. (6.71%), Eagle Asset Management Inc. (3.70%), Riverbridge Partners LLC (3.01%), Carillon Tower Advisers Inc. (2.94%) and Bank of New York Mellon Corp (2.33%). Company insiders that own Evolent Health stock include Cheryl Scott, Doug S Aron, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Lydia Stone, Michael D'amato, Seth Blackley and Thomas Peterson III. View institutional ownership trends for Evolent Health.

EVH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Silvercrest Asset Management Group LLC, Riverbridge Partners LLC, Carillon Tower Advisers Inc., Eagle Asset Management Inc., Granahan Investment Management Inc. MA, and Pictet Asset Management Ltd.. View insider buying and selling activity for Evolent Health.

EVH stock was acquired by a variety of institutional investors in the last quarter, including DC Investments Management LLC, Bank of New York Mellon Corp, State Street Corp, Rock Point Advisors LLC, JPMorgan Chase & Co., King Luther Capital Management Corp, Profit Investment Management LLC, and Two Sigma Advisers LP. Company insiders that have bought Evolent Health stock in the last two years include Doug S Aron, Kenneth A Samet, Michael D'amato, and Seth Blackley. View insider buying and selling activity for Evolent Health.

Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EVH stock can currently be purchased for approximately $6.19.

Evolent Health has a market capitalization of $529.12 million and generates $846.38 million in revenue each year. The technology company earns $-301,970,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Evolent Health employs 3,400 workers across the globe.

The official website for Evolent Health is www.evolenthealth.com.

Evolent Health's mailing address is 800 NORTH GLEBE ROAD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000.